Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open Label, Safety Study of INXN-4001 Delivered Via Retrograde Coronary Sinus Infusion in Patients With an Outpatient Left Ventricular Assist Device (LVAD)

NCT03409627 is registered in ClinicalTrials.gov with Triple-Gene, LLC as lead sponsor.

NCT NCT03409627
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03409627 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open Label, Safety Study of INXN-4001 Delivered Via Retrograde Coronary Sinus Infusion in Patients With an Outpatient Left Ventricular Assist Device (LVAD)
Lead sponsor
Triple-Gene, LLC
Phase
Phase 1
Overall status
Completed
Start date
April 9, 2018
Completion date
August 12, 2020
Enrollment
12 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular diseases, heart failure, heart-assist device